Researchers discover a new class of synapse-saving proteins

Researchers at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have discovered a new class of proteins that protect synapses from being destroyed. Synapses are the structures where electrical impulses pass from one neuron to another.

The discovery, published July 13 in the journal Nature Neuroscience, has implications for Alzheimer's disease and schizophrenia. If proven, increasing the number of these protective proteins could be a novel therapy for the management of those diseases, researchers said.

In Alzheimer's disease, loss of synapses leads to memory problems and other clinical symptoms. In schizophrenia, synapse losses during development predispose an individual to the disorder.

We are studying an immune system pathway in the brain that is responsible for eliminating excess synapses; this is called the complement system. Complement system proteins are deposited onto synapses. They act as signals that invite immune cells called macrophages to come and eat excess synapses during development. We discovered proteins that inhibit this function and essentially act as 'don't eat me' signals to protect synapses from elimination."

Dr. Gek-Ming Sia, PhD, assistant professor of pharmacology in UT Health San Antonio's Long School of Medicine and senior author of the research

The system sometimes goes awry

During development, synapses are overproduced. Humans have the most synapses at the ages of 12 to 16, and from then to about age 20, there is net synapse elimination that is a normal part of the brain's maturation. This process requires the complement system.

In adults, synapse numbers are stable, as synapse elimination and formation balance out. But in certain neurological diseases, the brain somehow is injured and begins to overproduce complement proteins, which leads to excessive synapse loss.

"This occurs most notably in Alzheimer's disease," Dr. Sia said.

In mouse models of Alzheimer's disease, researchers have found that the removal of complement proteins from the brain protects it from neurodegeneration, he said.

"We've known about the complement proteins, but there was no data to show that there were actually any complement inhibitors in the brain," Dr. Sia said. "We discovered for the first time that there are, that they affect complement activation in the brain, and that they protect synapses against complement activation."

Future directions

Dr. Sia and his colleagues will seek to answer interesting questions, including:

  • Whether complement system biology can explain why some people are more resistant and more resilient against certain psychiatric disorders;
  • How the number of complement inhibitors can be changed and whether that could have clinical ramifications;
  • Whether different neurons produce different complement inhibitors, each protecting a certain subset of synapses.

Regarding the last question, Dr. Sia said:

"This could explain why, in certain diseases, there is preferential loss of certain synapses. It could also explain why some people are more susceptible to synapse loss because they have lower levels of certain complement inhibitors."

The researchers focused on a neuronal complement inhibitor called SRPX2. The studies are being conducted in mice that lack the SRPX2 gene, that demonstrate complement system overactivation and that exhibit excessive synapse loss.

Acknowledgments

This project is funded by a NARSAD Young Investigator Award from the Brain and Behavior Research Foundation, a grant from the William and Ella Owens Medical Research Foundation, a Rising STARs Award from The University of Texas System, and grants from two branches of the U.S. National Institutes of Health - the National Institute of Neurological Disorders and Stroke, and the National Institute on Deafness and Other Communication Disorders.

Source:
Journal reference:

Cong, Q., et al. (2020) The endogenous neuronal complement inhibitor SRPX2 protects against complement-mediated synapse elimination during development. Nature Neuroscience. doi.org/10.1038/s41593-020-0672-0.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 vaccine uptake higher in people with mental illness but drops for those not on medication